Patent 11548880 was granted and assigned to Global Blood Therapeutics on January, 2023 by the United States Patent and Trademark Office.
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.